Table 2 Demographic, clinical and inflammatory data for Controls (n = 32) and ESRD patients on hemodialysis treatment (n = 289).

From: Interleukin 6 (rs1800795) and pentraxin 3 (rs2305619) polymorphisms-association with inflammation and all-cause mortality in end-stage-renal disease patients on dialysis

 

Control

ESRD

p value

Gender, n (%)

Male

13 (40.6)

158 (54.7)

0.131

Female

19 (59.4)

131 (45.3)

Age, years

55.8 ± 4.8

68.7 ± 13.6

 < 0.001

Etiology of CKD, n (%)

Diabetic nephropathy

–

101 (34.9)

–

Hypertensive nephrosclerosis

36 (12.5)

Polycystic kidney disease

19 (6.6)

Chronic glomerulonephritis

23 (8.0)

Other

44 (15.2)

Undetermined

66 (22.8)

Dialysis vintage, years

–

3.74 (1.65–7.34)

–

Dialysis therapy, n (%)

Hemodialysis

–

41 (14.2)

–

On-line hemodiafiltration

248 (85.8)

Vascular access, n (%)

Arteriovenous fistula

–

233 (80.6)

–

Arteriovenous graft

14 (4.8)

Catheter

42 (14.5)

Inflammatory biomarkers

Leukocytes × 109/L

5.30 (4.55–6.50)

6.31 (5.29–7.62)

0.004

hsCRP, mg/dl

0.15 (0.04–0.26)

0.37 (0.16–0.81)

 < 0.001

IL6, pg/ml

1.12 (0.74–1.62)

4.10 (2.69–7.33)

 < 0.001

PTX3, ng/ml

0.58 (0.42–0.73)

1.40 (0.98–2.05)

 < 0.001

GDF15, ng/ml

0.96 (0.80–1.09)

10.77 (7.90–13.74)

 < 0.001

  1. Data are presented as mean ± standard deviation or as median (interquartile range). Multiple comparisons between groups were performed by the Pearson’s Chi-squared test, by the one-way Anova with Bonferroni post-hoc tests or by the Mann–Whitney U test, as appropriate. Italic denotes p-values and bold-italic statistically significant p-values.
  2. CKD chronic kidney disease, GDF15 growth differentiation factor 15, hsCRP high-sensitivity C-reactive protein, IL6 interleukin 6, PTX3 pentraxin 3.
Back to article page